| |
AS Patients (n =55)
|
Controls (n = 33)
|
p value
|
|---|
|
Age (years)
|
36 (19–61)
|
39 (23–48)
|
0.9
|
|
Sex (M/F)
|
48/7
|
24/9
|
0.1
|
|
BMI (kg/m
2
)
|
25 (18–37)
|
25 (20–31)
|
0.9
|
|
Waist circumference (cm)
|
92 (66–120)
|
89 (65–104)
|
0.2
|
|
BMD-Lumbar spine (g/cm2)
|
0.9 (0.7–1.6)
|
1 (0.8–1.2)
|
0.1
|
|
BMD-Femoral neck (g/cm2)
|
0.8 (0.5–1.1)
|
0.9 (0.6–1.1)
|
0.002
|
|
ESR (mm/h)
|
17 (3–72)
|
9 (1–30)
|
<0.0001
|
|
hs-CRP (mg/L)
|
8.5 (0.6–24.3)
|
2.5 (0–9.9)
|
<0.0001
|
|
IL-6 (pg/mL)
|
18.5 (5–545)
|
8.1 (4–69)
|
<0.0001
|
|
IFNγ (pg/mL)
|
0.002 (0.002–1.956)
|
0.002 (0.002–0.313)
|
0.5
|
|
BAP (U/L)
|
29 (13–107)
|
26 (2–51)
|
0.1
|
|
Calcium (mg/L)
|
10 (9–11)
|
9.9 (9.3–11)
|
0.7
|
|
Phosphor (mg/dL)
|
1.3 (1.7–4.7)
|
3.4 (2.2–4,5)
|
0.9
|
|
Vitamin D (nM)
|
87 (4–266)
|
102 (10–303)
|
0.5
|
|
NTX (nM, bone collagen
equivalent)
|
82 (52–188)
|
84 (57–106)
|
0.3
|
|
TRAP 5 (U/L)
|
3.8 (2.3–6.6)
|
3.7 (2.3–8.34)
|
0.3
|
|
hPTH (pg/mL)
|
46 (44–170)
|
78 (45–180)
|
0.02
|
|
sRANKL (pmol/L)
|
284 (101–1598)
|
292 (143–783)
|
0.8
|
|
OPG (pg/mL)
|
339 (52–1118)
|
527 (16–1030)
|
0.02
|
|
sRANKL/OPG
|
0.99 (0.14-22.6)
|
0.65 (0.14–25.1)
|
0.04
|
|
Sclerostin (pmol/L)
|
73 (48–126)
|
77 (49–110)
|
0.2
|
|
sFRP1 (ng/mL)
|
0.14 (0.1–16.7)
|
0.2 (0.1–1.2)
|
0.4
|
|
DKK1 (pg/mL)
|
97 (17–771)
|
115 (29–278)
|
0.7
|
- Data are presented as the median with minimum and maximum values. ESR= erythrocyte sedimentation rate, hs-CRP= high sensitive C- reactive protein, IL-6= interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1.
